

DECCAN PHARMA JOURNAL SERIES

ARMS Online Publications

www.deccanpharmajournals.com

(Research Article)

Received; accepted

PREPARATION AND CHARACTERIZATION OF SPRAY DRIED MICROPARTICLE OF CELECOXIB

Mudit Dixit*, Gowrav M P, R.Panner Selvam, P.K.Kulkarni

Department of Pharmaceutics, J.S.S College of Pharmacy, J.S.S. UNIVERSITY, S.S Nagar, Mysore
570015, India

Keywords:

Spray drying, microparticle,
Celecoxib, Solubility
dissolution, crystallinity

For Correspondence:

Mudit Dixit

Department of
Pharmaceutics, J.S.S
College of Pharmacy, J.S.S.
UNIVERSITY, S.S Nagar,
Mysore 570015, India

E-mail:

muditdixit911@gmail.com

ABSTRACT

Celecoxib, an antiepileptic drug, exhibits poor water solubility and flow properties, poor dissolution and poor wetting. Consequently, the aim of this study was to improve the dissolution of Celecoxib. Microparticle containing Celecoxib was produced by spray drying using Isopropyl alcohol and water in the ratio of 40:60 (v/v) as solvent system to enhance dissolution rate. The prepared formulations were evaluated for in vitro dissolution and solubility. The prepared drug particles were characterized by scanning electron microscopy (SEM), differential scanning calorimeter (DSC), X-ray diffraction (XRD) and Fourier transform infrared spectroscopy (FT-IR). Dissolution profile of the spray dried microparticle was compared with pure sample and recrystallized sample. Spray dried microparticle exhibited decreased crystallinity and improved micromeritic properties. The dissolution of the Spray dried microparticle was improved compared with recrystallized and pure sample of Celecoxib. Consequently, it was believed that spray drying of Celecoxib is a useful tool to improve dissolution. Hence this spray drying technique can be used for formulation of tablets of Celecoxib by direct compression with directly compressible tablet excipients.

INTRODUCTION

Formulation and manufacture of solid oral dosage forms, and tablets in particular, have undergone rapid change and development over the last several decades. One of the most revolutionary technologies is that of direct compression. Direct compression is economical, facilitates processing without the need of moisture, heat and involves small number of processing steps. In direct tableting method, it is necessary to increase flow-ability and compressibility of the bulk powder in order to retain a steady supply of powder mixture to the tableting machine and sufficient mechanical strength of the compacted tablets. In addition to increasing efficiency of the manufacturing process it is also important to increase bioavailability of the drug by improving the solubility of the bulk drug powder. Spray dried¹ microparticle is one of such techniques to improve the micromeritic properties and dissolution of drug.

Consequently, many hydrophobic drugs show erratic and incomplete absorption from the gastrointestinal tract of animals and humans, which may lead to therapeutic failure. Thus, one of the major challenges to drug development today is poor solubility, as an estimated 40% of all newly developed drugs are poorly soluble or insoluble in water^{2, 3, 4, 5, 6}. As a result, much research has been conducted into methods of improving drug solubility and dissolution rates to increase the oral bioavailability of hydrophobic drugs. Various techniques such as melt adsorption, supercritical fluid processes, using different composition of solvents to prepared the microparticle to improve the dissolution rate of poorly water

soluble drugs. and amorphous state to improve their dissolution^{1,7,8}. Manipulation of the solid state by decreasing crystallinity of drug substances through formation of solid dispersion is one of the methods used for promoting drug dissolution 6-9. The solid dispersion technique has often proved to be the most successful in improving the dissolution and bioavailability of poorly water soluble active pharmaceutical ingredients because it is simple, economic, and advantageous technique. The concept of solid dispersion covers a wide range of systems. The enhancement in the dissolution rate is obtained by one or a combination of the following mechanisms: eutectic formation, increased surface area of the drug due to precipitation in the carrier, formation of true solid solution, improved wett-ability, and drug precipitation as a meta-stable crystalline form or a decrease in substance crystallinity. The type of solid dispersion formed depends on both the carrier-drug combination and the method of manufacture. Microwaves irradiation was used recently for the preparation of solvent-free solid dispersions and for enhancement of release of the poorly soluble drug, Spray drying is one such technique of preparing solid dispersion and is widely used as an alternative to milling to reduce particle size. The technique also has the advantages of being free from organic solvents compared to spray drying. The method has also been used by the food industry, for example, to encapsulate vitamins and minerals. Celecoxib, 4-[5-(4-methylphenyl)-3-(trifluoromethyl) - 1H-pyrazol-1-yl] benzene sulphonamide, belongs to a novel class of agents that selectively inhibit

cyclooxygenase- 2 (COX-2) enzymes. The introduction of this first selective COX-2 inhibitor (375-fold selectivity) (^{9,10}) in the pharmaceutical market revolutionized the treatment of osteoarthritis (OA), rheumatoid arthritis (RA), and management of pain. It is one of the top selling molecules (ranked 8th), with a worldwide sales of \$2614 million in year 2000, (^{11,12,13,14}). US FDA has approved its use in OA, RA, and dysmenorrhea with dose strengths of 100–200 mg once/twice daily. According to the biopharmaceutical classification system (BCS), celecoxib is an extreme example of a class II compound meaning that its oral bioavailability is determined by its dissolution rate in the GI tract. Consideration of the modified Noyes-Whitney equation provides some hints as to how the dissolution rate of very poorly soluble compounds might be improved to minimize the limitations to their oral availability. There have been numerous efforts to improve drug dissolution rates. These include (a) reducing the particle size to increase the surface area; (b) using water-soluble carriers to form inclusion complexes; (c) solubilization in surfactant systems; (d) using pro-drugs and drug derivatization; and (e) manipulation of the solid state of drug substances to improve the drug dissolution i.e. by reducing the crystallinity of drug substances through formation of solid dispersions.

The present work was conducted to improve the wettability, solubility and hence the dissolution of Celecoxib using spray drying techniques.

MATERIALS AND METHODS

Materials

Celecoxib was obtained as a gift sample from Micro Lab Ltd, Bangalore, India. Isopropyl alcohol was procured from Merck, Mumbai, India. All chemicals and buffers used were of analytical grade.

Preparation of microspheres

Microparticle prepared by spray drying

Spray dried particles consisted of Celecoxib was prepared by dissolving the about 2 gm drug in the mixture of Isopropyl alcohol /water (40:60 (v/v) ratio) solution. The solution was spray dried using Mini Spray Dryer LSD -48; (Jay instrument & systems Pvt. Ltd. Mumbai) at a Feed rate of 12%, an vacuum in the system -65 MM WC, Atomization pressure rate 1 kg/cm², Aspirator level at 35%, inlet temperature at 115 ±2°C and outlet temperature at 45 ±1°C. The formed microparticle were separated using cyclone separator, collected and stored in a desiccators at ambient temperature until ready to be used.

Recrystallization of Celecoxib

Changes in crystal lattice, being induced by solvents, can influence the physicochemical properties of the substance. Hence the mechanical, micromeritic and dissolution properties of microspheres were compared with commercial sample and recrystallized sample. Recrystallization of Celecoxib was carried out using same solvent composition as was used for spray drying Celecoxib was dissolved in 40 ml of Isopropyl alcohol and 60 ml of water with occasional stirring for 30 min. The crystals of Celecoxib were collected by filtration and were dried at 45°C.

Evaluation of microparticle

Determination of percentage yield and Drug content

The percentage yield of each formulation was determined according to the total recoverable final weight of microparticle and the total original weight of Celecoxib.

Microparticle⁷ (50 mg) were triturated with 10 ml of water. Allowed to stand for 10 min with occasional swirling and methanol was added to produce 100 ml. After suitable dilution, samples were measured at 251 nm. Drug content was determined from standard plot.

Differential scanning calorimetry (DSC)

A DSC study was carried out to detect possible polymorphic transition during the crystallization process. DSC measurements were performed on a DSC DuPont 9900, differential scanning calorimeter with a thermal analyzer.

Fourier transform infrared (FTIR) spectroscopy

The FTIR spectral measurements were taken at ambient temperature using a Shimadzu, Model 8033 (USA). Samples were dispersed in KBr powder and the pellets were made by applying 5 ton pressure. FTIR spectra were obtained by powder diffuse reflectance on FTIR spectrophotometer.

X-ray analysis

X-Ray powder diffraction patterns were obtained at room temperature using a Philips X' Pert MPD diffractometer, with Cu as anode material and graphite monochromator, operated at a voltage of 40 mA, 45 kV. The process parameters used were set as scan step size of 0.0170 (2θ).

Scanning electron microscopy (SEM)

Scanning electron microscopic (Joel- LV-5600, USA, with magnification of 250x) photographs were obtained to identify and confirm spherical nature and Surface topography of the crystals.

Micromeritic properties

Particle size of recrystallized sample, pure samples, spays dried microparticle were determined by microscopic method using calibrated ocular micrometer. Apparent particle densities of microparticle were measured using a Pycnometer. Carr's index was determined from powder volumes at the initial stage and after 1250 tappings to constant volume (Electrolab, Mumbai). The angle of repose of microparticle and commercial crystals was measured by fixed funnel method.

Mechanical Property

Mechanical Properties like tensile strength of microparticle, recrystallized sample and pure sample of Celecoxib were determined by compressing 500 mg of samples using hydraulic press at different ton/cm² for 1 min. The compacts stored in desiccators for overnight to allow elastic recovery. The thickness and diameter were measured for each compact. The hardness of each compact was then measured using Pfizer hardness tester. The tensile strength (σ) of the compact (ton/cm²) was calculated using following equation.

$$\sigma = 2F/\pi Dt$$

Where, F, D and t are hardness (ton), compact diameter (cm) and thickness (cm), respectively.

Solubility studies

The solubility of Celecoxib microparticle in water was determined by taking excess quantity of microparticle in 50 ml to screw-

capped glass vials filled with water. The vials were shaken for 24 hours on mechanical shaker. The solution was filtered through Whatmann filter paper No.1 and drug concentration was determined at 251 nm.

Dissolution studies of microparticle

The dissolution of Celecoxib pure sample, microparticle (prepared by spray drying) and recrystallized sample was determined by using USP dissolution apparatus XXIV-Type II (Electro Lab, Mumbai). Dissolution medium was 900 ml 7.4 Phosphate buffer. The amount of dissolved drug was determined using UV spectrophotometric method (UV 1601 A Shimadzu, Japan) at 251 nm.

RESULTS AND DISCUSSION:


The solvents chosen for the spray drying were acetone and water. These both the solvent were miscible in any proportion with each other.

The spray dried microparticle was collected and powders were free-flowing and white in color. The percentage yield of spray dried microparticle of Celecoxib was found to be 71%. This small yield can be increase by adding of solid substance or in large scale production as it was small scale preparation.

Drug content for the spray dried formulation was found to be 98.22 ± 0.015 .


The DSC thermogram (fig. 1) shows a sharp endothermic peak for all the Celecoxib. This one step melt might be due to only one crystal form (Triclinic) of the Celecoxib formed during the crystallization process, thus indicating that Celecoxib did not undergo any crystal modification.

The temperature range of the endothermic peak of all the Celecoxib crystals lies in the range of $158-161^{\circ}\text{C}$. Melting points show slight variation as the nature of the crystals might have been affected by the solvent. The Celecoxib pure sample melted at 161°C with enthalpy of 196.6 J/g . The melting endotherm for spray dried microparticle of Celecoxib was 158.12°C with decreased enthalpy of (168.17 J/g) indicating decreased crystallinity or presence of amorphous form. The DSC thermograms of recrystallized sample of Celecoxib showed melting endotherm at the characteristic endothermic peak for the drug at 160.43°C with enthalpy of 192.73 J/g indicating decreased crystallinity but not compare to spray dried microparticle as spray dried microparticle shows more decreased crystallinity then others samples of Celecoxib.

Figure-1 DSC spectra of different samples of Celecoxib

All the crystals have exhibited general characteristic peaks at 1164 and 1347 cm^{-1} , respectively. Medium intensity bands at 3338 and 3232 cm^{-1} were seen as a doublet, which are attributed to the N–H stretching vibration of $-\text{SO}_2\text{NH}_2$ group. The C–N stretching band observed at 1397 and 1388 cm^{-1} for prepared microspheres (Fig. 2), In FT-IR studies, Specific


changes in IR spectra are not very clear, could be due to variations in the resonance structure, rotation of a part of a molecule or certain bonds. Alteration could be due to minor distortion of bond angles, or even a result of the presence of a solvent of crystallization.

Figure 2 FT-IR spectra of different samples of Celecoxib

All the samples showed similar peak positions (2θ) in X-ray diffraction, formation of different polymorphs of Celecoxib was ruled out. However relative intensities of XRD peaks were modified (fig. 3). In XRD analysis, XRD peaks were modified. This could be attributed to the markedly different crystal habits of the samples.

Therefore the relative abundance of the planes exposed to the X-ray source would have been altered, producing the variations in the relative intensities of the peak or may be due to differences in particle sizes.


Figure-3 XRD spectra of different samples of Celecoxib



The SEM images of all the formulation shown in figs 4. The size of spray dried microparticle was in small in size and has smooth surface. Particle of pure sample are of the smallest size (6-11 μm) and they have irregular shapes.

Recrystallization produced crystals with intermediate size (4-28 μm). The particle formed by spray microparticle formed by spray drying technique and the resultant Microparticle had a smooth surface. Microparticel obtained were spherical in shape with small size (3-11 μm).

Figure 4- SEM graphs of different samples of Celecoxib



The Micrometrics properties of Pure Sample, Recrystallized Sample and spray dried microparticle of Celecoxib shown below: (Table 1).

Table-1 micrometrics property of Celecoxib of different samples

Properties	Pure sample	Recrystallized Sample	Spray dried microparticle
Particle size (µm)	6-11	4-28	3-11
Flow rate (gm/Sec)	No flow	No flow	2.32
Angle of repose	41.12	32.37	22.87
Tapped density (gm/ml)	0.8332±0.01	0.7893±0.012	0.4173±0.04
Bulk density(gm/ml)	0.5783±0.01	0.3953±0.01	0.1953±0.02
Carr's index	42.21	34.42	15.63
Porosity (%)	9.54	18.45	29.56

Spray dried microparticle exhibited superior compressibility characteristics compared to pure sample and recrystallized sample (fig. 5). The superior compressibility characteristics of Spray dried microparticle could be due to the fact that during the process of compression fresh surfaces are formed by fracturing crystals. Surface

freshly prepared by fracture enhanced the plastic inter particle bonding, resulting in a lower compression force required for compressing the microparticle under plastic deformation compared to that of single crystal. Tensile strength of the Celecoxib exhibited compressibility as follow: pure sample □ recrystallized sample □ spray dried microparticle.





Figure 5– Tensile strength of P.S-pure Sample, R.S-Recrystallized sample, S.M-spray dried microparticle

The solubility of Celecoxib spray dried microparticle in water was found to be (0.0427 mg/ml) which was higher greater than recrystallized sample (0.0095 mg/ml) and pure sample (0.0078 mg/ml). In solubility studied result shown that spray dried particle shows improve solubility then recrystallized sample and pure drug sample. This could be due to the increasing in wettability and reduction in particle size and could be due to the particle has uniform size of microparticle. According to above result spray drying technique has good ability to

increasing the solubility of poorly water soluble drug.

The dissolution profiles of Celecoxib (fig. 6) exhibited improved dissolution behavior for spray dried microparticle than recrystallized sample and pure sample. The dissolution of spray dried microparticle shows improves dissolution rate compare to other samples. The reason for this faster dissolution could be linked to the better wet-ability of the microparticle. The amount of drug dissolved in 60 min greatly varied for spray dried microparticle.

Figure-6 Shows Dissolution of: P.S-pure drug sample, R.S- recrystallized sample, S.DM-spray dried microparticle



CONCLUSION:

Spray dried microparticle of Celecoxib were prepared by spray drying technique to improve the dissolution rate. Spray dried microparticle exhibited decreased crystallinity and improved Micromeritic & Mechanical properties. DSC and XRD studies showed that there is no change in the crystal structure of Celecoxib during the

spray drying process i.e., polymorphism has not occurred. The solubility and dissolution of the spray dried microparticle was improved compared with Recrystallized sample and pure sample.

Hence this spray drying technique can be used for formulation of tablets of Celecoxib by direct compression with directly compressible tablet excipients.

ACKNOWLEDGEMENTS

The authors are thankful to Micro labs, Bangalore, India for the gift sample of celecoxib, and Principal, J.S.S.College of Pharmacy, Mysore for providing facilities to carry out this work.

REFERENCES

1. Killeen M.J., "The process of spray drying and spray congealing". *Pharm. Eng*, 1993; **13**: 56-64.
2. Corrigan D.O. Corrigan O.I. and Healy A.M., "Predicting the physical state of spray dried composites: salbutamol sulphate/lactose and salbutamol sulphate/polyethylene glycol co-spray dried systems", *Int. J. Pharm*, 2004; **273**: 171-182.
3. Maa Y.F. Nguyen P.A. Hsu C.C. and Sit K., "Spray drying performance of bench-top spray dryer for protein aerosol powder preparation", *Biotech. Bioeng.* 1998; **60**: 301-309.
4. Amal A.E. and Ebtessam A.E., "Dissolution of ibuprofen from spray dried and spray chilled particles" *pak. j. pharm. sci*, 2010; **23**: 284-290.
5. Paradkar A.R. Chauhan B. Ketkar A.R. and Maheshwari M., "Preparation and evaluation of ibuprofen beads by melt solidification technique", *Int. J. Pharm*, 2003; **255**: 33-42.
6. Schwendeman S.P. Alonso M.J. Joworowicz M. Langer R. and Tobio M., "New strategies for the microencapsulation of tetanus vaccine, *J. Microencapsulation*, 1998; **15**: 299-318.
7. Serajuddin A.T., "Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs", *J. Pharm. Sci*, 1999; **88**: 1058-1066.
8. Vasconcelos T. Costa P. and Sarmiento B., "Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs", *Drug Discov. Today*, 2007; **12**: 1068-1075.
9. Yajima T. Itai S. and Umeki N., "Optimum spray congealing conditions for masking the bitter taste of chloramphenicol in wax matrix", *Chem. Pharm. Bull*, 1999; **47**: 220-225.
10. Clemett D. Goa K.L., "Celecoxib a review of its use in osteoarthritis, rheumatoid arthritis and acute pain", *Drugs*, 2000; **59**: 957-980.
11. Anonymous., "50 top selling drugs ranked by worldwide sales for 2000, Patent scan—a monthly proactive patents bulletin for pharmaceutical industry", *Med. Ad News*, 2001; **2**: (12).
12. Cook TC, Karim A. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. *J. Pharmacol. Exp. Ther.* 2001, **297**, 638-645.
13. Dev R.V. Rekha K.S. Vyas K. Mohanti S.B. Kumar P.R. Reddy G.O., "Celecoxib, a COX-II inhibitor", *Acta Cryst*, 1999; **C55**.
14. Kakumanu V. Bansal A., "Enthalpy relaxation studies of celecoxib amorphous mixtures", *Pharm. Res*, 2002; **19**: 1873-1878.